Compton Peggy A, Wu Stephen M, Schieffer Beatrix, Pham Quynh, Naliboff Bruce D
Acute Care Section, School of Nursing at UCLA, Los Angeles, California 90095-6918, USA.
J Pain Symptom Manage. 2008 Oct;36(4):383-95. doi: 10.1016/j.jpainsymman.2007.11.006. Epub 2008 Jun 3.
The Prescription Drug Use Questionnaire (PDUQ) is one of several published tools developed to help clinicians better identify the presence of opioid abuse or dependence in patients with chronic pain. This paper introduces a patient version of the PDUQ (PDUQp), a 31-item questionnaire derived from the items of the original tool designed for self-administration, and describes evidence for its validity and reliability in a sample of patients with chronic nonmalignant pain and on opioid therapy. Further, this study examines instances of discontinuation from opioid medication treatment related to violation of the medication agreement in this population, and the relationship of these with problematic opioid misuse behaviors, PDUQ and PDUQp scores. A sample of 135 consecutive patients with chronic nonmalignant pain was recruited from a multidisciplinary Veterans Affairs chronic pain clinic, and prospectively followed over one year of opioid therapy. Using the PDUQ as a criterion measure, moderate to good concurrent and predictive validity data for the PDUQp are presented, as well as item-by-item comparison of the two formats. Reliability data indicate moderate test stability over time. Of those patients whose opioid treatment was discontinued due to medication agreement violation-related discontinuation (MAVRD) (n=38 or 28% of sample), 40% of these (n=11) were due to specific problematic opioid misuse behaviors. Based upon specificity and sensitivity analyses, a suggested cutoff PDUQp score for predicting MAVRD is provided. This study supports the PDUQp as a useful tool for assessing and predicting problematic opioid medication use in a chronic pain patient sample.
《处方药使用问卷》(PDUQ)是已发表的几种工具之一,其开发目的是帮助临床医生更好地识别慢性疼痛患者中阿片类药物滥用或依赖的情况。本文介绍了PDUQ的患者版本(PDUQp),这是一份由原始工具项目衍生而来的31项问卷,专为患者自行填写设计,并描述了其在慢性非恶性疼痛且接受阿片类药物治疗的患者样本中的有效性和可靠性证据。此外,本研究调查了该人群中因违反用药协议而停止阿片类药物治疗的情况,以及这些情况与有问题的阿片类药物滥用行为、PDUQ和PDUQp评分之间的关系。从一家多学科退伍军人事务慢性疼痛诊所招募了135名连续的慢性非恶性疼痛患者样本,并对其进行了为期一年的阿片类药物治疗前瞻性随访。以PDUQ作为标准测量工具,给出了PDUQp的中度至良好的同时效度和预测效度数据,以及两种格式的逐项比较。可靠性数据表明随着时间推移测试稳定性适中。在因违反用药协议相关停药(MAVRD)而停止阿片类药物治疗的患者中(n = 38,占样本的28%),其中40%(n = 11)是由于特定的有问题的阿片类药物滥用行为。基于特异性和敏感性分析,提供了一个用于预测MAVRD的建议PDUQp评分临界值。本研究支持将PDUQp作为评估和预测慢性疼痛患者样本中有问题的阿片类药物使用情况的有用工具。